<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589897</url>
  </required_header>
  <id_info>
    <org_study_id>JMR1075-100</org_study_id>
    <nct_id>NCT04589897</nct_id>
  </id_info>
  <brief_title>Manuka Honey Sinus Rinse Study</brief_title>
  <official_title>A Pilot Study Investigating the Effects of a Manuka Honey Sinus Rinse on Sino-nasal Outcome Test Scores in Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swansea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swansea University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial investigating the effect of a sinus rinse in people with CF&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      People with with CF often have bacterial infection in their air ways. There is great interest&#xD;
      in the different types of bacteria found within these infections.&#xD;
&#xD;
      This clinical trial looks at whether a novel sinus rinse device (that incorporates manuka&#xD;
      honey) could help clear infection or reduce the amount and/or types of bacteria found within&#xD;
      the upper airway. This study assesses the changes in the Sino-Nasal Outcome Test (SNOT-22)&#xD;
      scores along with any changes in quality of life, before and after the use of a sinus rinse&#xD;
      device for 30 days.&#xD;
&#xD;
      In addition to this, the amount and types of bacteria found in nasal swabs, the sinus rinse&#xD;
      solution, and sputum samples, before and after using the sinus rinse device will be&#xD;
      investigated. Sputum samples will also be monitored for changes in composition before and&#xD;
      after using the sinus rinse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sino-Nasal Outcome Test 22 (SNOT- 22) Score</measure>
    <time_frame>Baseline and day 30 (+-7 days)</time_frame>
    <description>Does the addition of manuka honey to the sinus rinse change the Sino Nasal Outcome Test (SNOT)-22 score of patients with cystic fibrosis? The SNOT-22 scale runs from 0 -110 and a higher score indicating worse symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score</measure>
    <time_frame>Baseline and day 30 (+-7 days)</time_frame>
    <description>Does the addition of manuka honey to a sinus rinse change the CFQ-R score in patients with cystic fibrosis? The scale runs from 1-100 and a higher score indicates a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial type and number</measure>
    <time_frame>Baseline and day 30 (+-7 days)</time_frame>
    <description>Does the addition of manuka honey to a sinus rinse impact on the bacterial type/amount found in the nasal/paranasal cavities of patients with cystic fibrosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Infection, Bacterial</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manuka honey sinus rinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard sinus rinse</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Manuka honey sinus rinse</intervention_name>
    <description>Will follow a modified NHS nasal rinse protocol with the addition of manuka honey</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard sinus rinse</intervention_name>
    <description>will follow the standard NHS nasal rinse protocol</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is willing and able to give informed consent.&#xD;
&#xD;
          -  The patient must be ≥ 18 years.&#xD;
&#xD;
          -  The patient must have an established diagnosis of CF (one or more of the following)&#xD;
             Sweat chloride &gt;60mEq/L Presence of two CF causing mutations.&#xD;
&#xD;
          -  The patient must have chronic symptoms of rhinosinusitis according to the criteria of&#xD;
             the European Position Paper on Rhinosinusitis (appendix A).&#xD;
&#xD;
          -  The patient scores greater ≥ 7 on their SNOT-22 questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has ever tested positive for the bacteria Mycobacterium tuberculosis.&#xD;
&#xD;
          -  The patient is currently using a nasal rinse protocol.&#xD;
&#xD;
          -  The patient has undergone sinus surgery within 6 months.&#xD;
&#xD;
          -  The patient suffers from nasal bleeding.&#xD;
&#xD;
          -  The patient is currently undergoing systemic antibiotic therapy for infective&#xD;
             exacerbation.&#xD;
&#xD;
          -  The patient is using overnight oxygen via nasal cannula.&#xD;
&#xD;
          -  The patient is participating in another clinical trial or has done so within the last&#xD;
             30 days.&#xD;
&#xD;
          -  The patient has a known allergy to bee products.&#xD;
&#xD;
          -  The patient has an objection to the use of bee products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Duckers</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Health Service, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rowena Jenkins</last_name>
    <phone>00 441792 602951</phone>
    <email>r.e.jenkins@swansea.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>All Wales Adult Cystic Fibrosis Center, University Hospital Llandough</name>
      <address>
        <city>Cardiff</city>
        <zip>CF62 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Duckers</last_name>
      <phone>02920 716488</phone>
      <email>Jamie.Duckers@wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data collected during the trial that underlie the results to be reported in an article after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

